Highlighting the Key Takeaways From ASH 2024

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

Now Viewing

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Summary of Recent Advancements in Lymphoma Treatment

This summary highlights Dr Andre Goy’s analysis of recent developments in lymphoma treatment approaches:

CAR T-Cell Therapy

• New CAR T constructs are being explored to improve efficacy, including anti-CD22 approaches and “off-the-shelf” options.
• MRD status post CAR T therapy strongly correlates with long-term outcomes.
• CAR T therapy demonstrates curative potential in approximately 40% of large cell lymphoma patients and 35% or more in mantle cell lymphoma.

Bispecific Antibodies

• Emerging as an important option for patients ineligible for CAR T or post CAR T relapse
• Currently, CAR T remains preferable for heavily pretreated relapsed patients as bispecifics have not yet demonstrated curative potential.
• Promising combinations with chemotherapy (eg, EPCO, miniCHOP) are being explored.
• Particularly appealing for follicular lymphoma, both as monotherapy and in combination with other biologics

Novel Therapeutic Approaches

• Tetrameric T-cell engagers with allogeneic natural killer cells showing promise in Hodgkin lymphoma, where CAR T has limited efficacy
• Bruton tyrosine kinase inhibition: A UK study demonstrated superiority of ibrutinib plus rituximab over bendamustine plus rituximab.
• The Triangle trial confirmed that when ibrutinib is combined with R-CHOP/R-DHAP, autologous transplant provides no additional benefit.

Treatment Sequencing and Personalization

• Alliance data showed patients with mantle cell lymphoma who achieve MRD negativity may not benefit from autologous consolidation.
• Increasing implementation of next-generation sequencing to guide therapy
• Growing enthusiasm for AI applications to analyze unstructured data and identify optimal treatment approaches

Key focus on determining optimal treatment sequences and addressing equity in care access